Clinically led, evidence based, AI powered

Our company

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology’.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L) and is based in the Schrödinger Building, located on Oxford Science Park.

Our people

Sensyne Health’s proven team has built multiple £500m+ health & technology businesses over the past 15 years including IPO, M&A experience in regulated healthcare and digital technologies, and is complemented by a multi-disciplinary team combining AI expertise with deep clinical experience.

View people

Strategic research agreements

Sensyne Health collaborates with NHS Trusts under strategic research agreements (SRAs) to combine clinical artificial intelligence technology (Clinical AI) with ethically-sourced, anonymised patient data to help improve patient care, accelerate the discovery and development of new medicines and improve our understanding of disease and treatment.

Find out more


Case studies, press releases and articles from opinion leaders and experts in the fields of digital healthcare, clinical AI and life sciences research. Plus details of events where you can meet our experts and hear them share their views on developments in their respective fields.

View latest news